Mental Health Clinics in Gallatin Gateway, MT Accepting Medicare
1 Mental Health Clinics found. Showing 1 - 1
 Vitality Therapeutics Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 47855 Gallatin Rd, Gallatin Gateway, MT 59730 Phone: 406-225-7797 |
News Archive
New Treatment for Chronic Head Pain
Dr. Levy pioneered a procedure known as supraorbital nerve stimulation or SOS, in which neurotransmitters are implanted into the forehead to block head pain. Tiny wires are burrowed under the skin until the precise location of pain is marked by a tingling response to electrical charge. The wires are kept in place for a week, and if pain is lessened and the patient is comfortable with the technology, neurotransmitters are surgically implanted under local anesthesia. The patient is able to control pain relief by manually adjusting the level of electrical stimulation through a hand held device.
Towns struggle with high health costs
In the final installment of a two-part series, The Boston Globe reports on municipal health costs and how financially strapped towns are seeking a change in state law so that they can have more flexibility in setting health costs.
Stage IIIB NSCLC patients may benefit from surgical resection in combination with chemo or radiation therapy
Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.
Asbury Communities offers management and support services for older adults
In 2010, more than 4 million baby boomers turned 50, according to the U.S. Census Bureau. Boomers today represent 28 percent of the U.S. population, or 76.1 million people. With so many people aging, how is the senior living industry going to provide services to this group of older Americans?
Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
› Verified 5 days ago